MCID: BLP003
MIFTS: 46

Blepharospasm

Categories: Neuronal diseases, Muscle diseases, Genetic diseases, Rare diseases, Eye diseases

Aliases & Classifications for Blepharospasm

MalaCards integrated aliases for Blepharospasm:

Name: Blepharospasm 12 76 54 29 55 6 44 15 40 73

Classifications:



External Ids:

Disease Ontology 12 DOID:529
ICD10 33 G24.5
ICD9CM 35 333.81
MeSH 44 D001764
NCIt 50 C118723
UMLS 73 C0005747

Summaries for Blepharospasm

NINDS : 54 Benign essential blepharospasm (BEB) is a progressive neurological disorder characterized by involuntary muscle contractions and spasms of the eyelid muscles. It is a form of dystonia, a movement disorder in which muscle contractions cause sustained eyelid closure, twitching or repetitive movements. BEB begins gradually with increased frequency of eye blinking often associated with eye irritation. Other symptoms may include increasing difficulty in keeping the eyes open, and light sensitivity. Generally, the spasms occur during the day, disappear in sleep, and reappear after waking. As the condition progresses, the spasms may intensify, forcing the eyelids to remain closed for long periods of time, and thereby causing substantial visual disturbance or functional blindness. It is important to note that the blindness is caused solely by the uncontrollable closing of the eyelids and not by a dysfunction of the eyes. BEB occurs in both men and women, although it is especially common in middle-aged and elderly women.

MalaCards based summary : Blepharospasm is related to lymphedema, hereditary, ii and oromandibular dystonia, and has symptoms including myoclonus, torticollis and spasmodic torticollis. An important gene associated with Blepharospasm is DRD5 (Dopamine Receptor D5). The drugs Acetylcholine and Silicon have been mentioned in the context of this disorder. Affiliated tissues include eye, brain and testes, and related phenotypes are mortality/aging and vision/eye

Disease Ontology : 12 A focal dystonia that is characterized by the involuntary, forcible contraction of the muscles controlling eye blinks.

Wikipedia : 76 Blepharospasm is any abnormal contraction or twitch of the eyelid. In most cases, symptoms last for a... more...

Related Diseases for Blepharospasm

Diseases in the Blepharospasm family:

Blepharospasm, Benign Essential

Diseases related to Blepharospasm via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 103)
# Related Disease Score Top Affiliating Genes
1 lymphedema, hereditary, ii 30.8 CAMP DRD5 GCH1 THAP1 TOR1A
2 oromandibular dystonia 28.8 CAMP GCH1 THAP1 TOR1A
3 movement disease 28.6 GCH1 TOR1A
4 hemidystonia 27.7 CAMP GCH1 THAP1 TOR1A
5 dystonia 27.6 DRD5 GCH1 GNAL THAP1 TIMM8A TOR1A
6 cervical dystonia 27.3 CAMP DRD5 GCH1 GNAL THAP1 TOR1A
7 cranio-facial dystonia 27.3 CAMP DRD5 GCH1 THAP1 TOR1A
8 focal dystonia 27.3 CAMP DRD5 GNAL THAP1 TIMM8A TOR1A
9 blepharospasm, benign essential 12.6
10 vernal keratoconjunctivitis 10.9
11 x-linked dystonia-parkinsonism/lubag 10.9
12 hemifacial spasm 10.5
13 cervicitis 10.3
14 spasmodic dysphonia 10.3 THAP1 TOR1A
15 dystonia 24 10.3 THAP1 TOR1A
16 multifocal dystonia 10.2 CAMP TOR1A
17 apraxia 10.2
18 torticollis 10.2
19 apraxia of eyelid opening 10.1
20 depression 10.0
21 strabismus 9.9
22 ptosis 9.9
23 bell's palsy 9.9
24 headache 9.9
25 eyelid disease 9.9 DRD5 HSPG2
26 schwartz-jampel syndrome, type 1 9.9
27 myasthenia gravis 9.8
28 myasthenia gravis congenital 9.8
29 myoclonus 9.8
30 spasticity 9.8
31 tremor 9.8
32 hemifacial spasm, familial 9.7
33 multiple system atrophy 1 9.7
34 schizophrenia 9.7
35 aging 9.7
36 entropion 9.7
37 dystonia 3, torsion, x-linked 9.7 GCH1 THAP1
38 thiamine metabolism dysfunction syndrome 2 9.6 GCH1 TOR1A
39 autoimmune disease 9.6
40 multiple sclerosis 9.6
41 facial spasm 9.6
42 corneal dystrophy, fuchs endothelial, 1 9.6
43 systemic lupus erythematosus 9.6
44 obsessive-compulsive disorder 9.6
45 cerebrotendinous xanthomatosis 9.6
46 tardive dyskinesia 9.6
47 mohr-tranebjaerg syndrome 9.6
48 supranuclear palsy, progressive, 1 9.6
49 xanthomatosis 9.6
50 astigmatism 9.6

Graphical network of the top 20 diseases related to Blepharospasm:



Diseases related to Blepharospasm

Symptoms & Phenotypes for Blepharospasm

UMLS symptoms related to Blepharospasm:


myoclonus, torticollis, spasmodic torticollis, erythema of the eyelids, oromandibular dystonia, lingual dystonia

MGI Mouse Phenotypes related to Blepharospasm:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 mortality/aging MP:0010768 9.5 DRD5 GCH1 GNAL HSPG2 THAP1 TOR1A
2 vision/eye MP:0005391 9.02 CAMP DRD5 HSPG2 THAP1 TOR1A

Drugs & Therapeutics for Blepharospasm

Drugs for Blepharospasm (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 56)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Acetylcholine Approved Phase 4,Phase 3,Phase 2,Not Applicable 51-84-3 187
2
Silicon Approved, Investigational Phase 4 7440-21-3 4082203
3 abobotulinumtoxinA Phase 4,Phase 3,Phase 2,Not Applicable
4 Cholinergic Agents Phase 4,Phase 3,Phase 2,Not Applicable
5 Neuromuscular Agents Phase 4,Phase 3,Phase 2,Not Applicable
6 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Not Applicable
7 onabotulinumtoxinA Phase 4,Phase 3,Phase 2,Not Applicable
8 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
9 Botulinum Toxins, Type A Phase 4,Phase 3,Phase 2,Not Applicable
10 Botulinum Toxins Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
11 incobotulinumtoxinA Phase 4,Phase 3,Phase 2
12
Propranolol Approved, Investigational Phase 2, Phase 3 525-66-6 4946
13 Anti-Arrhythmia Agents Phase 2, Phase 3
14 Pharmaceutical Solutions Phase 3
15 Adrenergic Agents Phase 2, Phase 3
16 Adrenergic Antagonists Phase 2, Phase 3
17 Adrenergic beta-Antagonists Phase 2, Phase 3
18 Vasodilator Agents Phase 2, Phase 3
19 Antihypertensive Agents Phase 2, Phase 3
20
Etanercept Approved, Investigational Phase 1, Phase 2 185243-69-0
21
Mexiletine Approved, Investigational Phase 2 31828-71-4 4178
22 Analgesics Phase 1, Phase 2
23 Gastrointestinal Agents Phase 1, Phase 2
24 Analgesics, Non-Narcotic Phase 1, Phase 2
25 Immunosuppressive Agents Phase 1, Phase 2
26 Anti-Inflammatory Agents Phase 1, Phase 2,Not Applicable
27 Anti-Inflammatory Agents, Non-Steroidal Phase 1, Phase 2
28 Antirheumatic Agents Phase 1, Phase 2
29 Autoantibodies Phase 1, Phase 2
30 Sodium Channel Blockers Phase 2
31 Diuretics, Potassium Sparing Phase 2
32
Zinc Approved, Investigational Not Applicable 7440-66-6 23994
33
Menthol Approved Early Phase 1 2216-51-5 16666
34
Ephedrine Approved 299-42-3 9294
35
Pseudoephedrine Approved 90-82-4 7028
36
Cortisone acetate Approved, Investigational Not Applicable 1950-04-4, 50-04-4 5745
37
Prednisolone Approved, Vet_approved Not Applicable 50-24-8 5755
38
Methylprednisolone Approved, Vet_approved Not Applicable 83-43-2 6741
39
Carbamazepine Approved, Investigational Not Applicable 298-46-4 2554
40 Micronutrients Not Applicable
41 Trace Elements Not Applicable
42 Prednisolone acetate Not Applicable
43
Cortisone Not Applicable 53-06-5 222786
44 Respiratory System Agents
45 Methylprednisolone acetate Not Applicable
46 Methylprednisolone Hemisuccinate Not Applicable
47 Nasal Decongestants
48 Tetrahydrozoline
49 Ophthalmic Solutions
50 Dihydroxyphenylalanine

Interventional clinical trials:

(show top 50) (show all 51)
# Name Status NCT ID Phase Drugs
1 Comparison of Two Botulinum Type A Products in the Treatment of Blepharospasm Completed NCT00761592 Phase 4
2 Efficacy and Safety Study of Meditoxin® to Treat Essential Blepharospasm Completed NCT01259557 Phase 4 Botulinum Toxin Type A
3 Functional Effects of Botox on the Brain Using MRS and fMRI Completed NCT03373162 Phase 4 onabotulinumtoxinA
4 Efficacy of Aurosling in Frontalis Sling Suspension Surgery Completed NCT00753831 Phase 4
5 Pretarsal Versus Preseptal Botulinum Toxin for Patients With Eyelid Spasm Active, not recruiting NCT03508882 Phase 4 Botulinum Toxin Type A 100Unit/Vial (Product);Saline Solution for Injection
6 Frontalis Botulinum Toxin Not yet recruiting NCT03186001 Phase 4 Abobotulinum toxin A
7 Evaluation of Botulinum Toxin Injection Efficacy in the Treatment of Head Essential Tremor Unknown status NCT02555982 Phase 3 BOTOX ® 200 Unités;Placebo
8 Comparison of Korean Botulinum Toxin Type A Versus Botox in the Treatment of Essential Blepharospasm Completed NCT00682760 Phase 3 Korean Botulinum toxin type A (KbtxA) and Botox injection
9 Clinical Study to Evaluate the Efficacy and Safety of Neuronox and Botox With Essential Blepharospasm Completed NCT03216473 Phase 3 Neuronox;Botox
10 IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Blepharospasm Completed NCT00406367 Phase 3 incobotulinumtoxinA (Xeomin);Placebo
11 Therapeutic Confirmatory Clinical Trial to Evaluate the Safety and Efficacy of "Hugeltox Inj." in Essential Blepharospasm Completed NCT01791881 Phase 3 Hugeltox;Botulinum Toxin Type A(Botox®)
12 Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Abnormal Contraction or Twitch of the Eyelid Completed NCT01896895 Phase 3 IncobulinumtoxinA (Xeomin), 25 Units;IncobotulinumtoxinA (Xeomin), 12.5 Units;Placebo;IncobotulinumtoxinA (Xeomin), 35 Units
13 Effects of Botulinum Toxin Injections in Patients With Hereditary Spastic Paraplegia Completed NCT02604186 Phase 2, Phase 3
14 Addressing Involuntary Movements in Tardive Dyskinesia Completed NCT02291861 Phase 3 SD-809;Placebo
15 Aim to Reduce Movements in Tardive Dyskinesia Completed NCT02195700 Phase 2, Phase 3 SD-809;Placebo
16 Safety and Efficacy of NABOTA in Treatment of Essential Blepharospasm Recruiting NCT02947815 Phase 2, Phase 3 Clostridium Botulinum Toxin Type A;Clostridium Botulinum Toxin Type A
17 Safety and Efficacy of Propranolol in the Treatment of Tardive Dyskinesia Recruiting NCT03254186 Phase 2, Phase 3 Propranolol Hydrochloride;Placebo Oral Tablet
18 ASIS for Enbrel in Plaque Psoriasis Unknown status NCT02112097 Phase 1, Phase 2 Gadolinium;Gadolinium;Gadolinium;Efficacy of Enbrel subcutaneously at Week 12;Efficacy of Enbrel subcutaneously at Week 24;Efficacy of Enbrel subcutaneously at Week 36;Efficacy of Enbrel subdermally at Week 12;Efficacy of Enbrel subdermally at Week 24;Efficacy of Enbrel subdermally at Week 36;PASI 75 n(%) subcutaneously at Week 12;PASI 75 n(%) subcutaneously at Week 24;PASI 75 n(%) subcutaneously at Week 36;PASI 75 n(%) subdermally at Week 12;PASI 75 n(%) subdermally at Week 24;PASI 75 n(%) subdermally at Week 36;Adverse Reactions of Enbrel subcutaneously;Adverse Reactions of Enbrel subdermally at Week 36;Gadolinium;Gadolinium;Gadolinium
19 A Study of Acetyl Hexapeptide-8 (AH8) in Treatment of Blepharospasm Completed NCT00942851 Phase 1, Phase 2 Acetyl-Hexapeptide Topical Treatment;placebo
20 Study of a Single Administration of 3 Doses of Dysport® for the Treatment of Benign Essential Blepharospasm Completed NCT00234507 Phase 2 Botulinum toxin type A (Dysport®)
21 Brain Stimulation to Treat Blepharospasm or Meige Syndrome Completed NCT00411255 Phase 2
22 Mexiletine for the Treatment of Focal Dystonia Completed NCT00001784 Phase 2 Mexiletine
23 Deep Brain Stimulation in Patients With Dystonia Completed NCT00773604 Phase 1, Phase 2
24 Administration of Expanded Autologous Adult Bone Marrow Mesenchymal Cells in Established Chronic Spinal Cord Injuries Completed NCT02570932 Phase 2
25 Acetyl Hexapeptide-8 for Blepharospasm Terminated NCT01750346 Phase 2 Topical acetyl hexapeptide-8;Placebo
26 Blepharospasm Short Interval Terminated NCT00507637 Phase 2 NT 201
27 Two Different Surgical Methods of Blepharospasm Unknown status NCT02765113 Early Phase 1
28 Comparison of Different Botulinum Toxin A Injection Patterns in the Treatment of Blepharospasm Unknown status NCT02327728 Not Applicable Botulinum toxin A 12.5U;Botulinum toxin A 10U
29 Influence of Gaze Shift and Emotions on Symptoms of Blepharospasm Unknown status NCT01759745
30 Testing the Effect of Zinc Supplementation to Improve the Treatment Effect of Botulinum Toxin for Oculofacial Spasm Unknown status NCT01546805 Not Applicable Zinc Supplement;Sugar pill
31 A Mechanical Device for Blepharospasm Completed NCT03269123 Not Applicable
32 Blepharospasm Patient Survey for Patients With Blepharospasm Completed NCT01686061
33 Trial Evaluating Xeomin® (incobotulinumtoxinA) for Cervical Dystonia or Blepharospasm in the United States Completed NCT01287247
34 rTMS and Botulinum Toxin in Benign Essential Blepharospasm Completed NCT02370875 Not Applicable
35 Brain Changes in Blepharospasm Completed NCT00500799
36 A Retrospective Chart Review of BOTOX® and Xeomin® for the Treatment of Cervical Dystonia and Blepharospasm Completed NCT01814774
37 A Retrospective Chart Review of BOTOX® and Xeomin® for the Management of Cervical Dystonia and Blepharospasm Completed NCT02245958
38 Movement Disorder Survey in East China Completed NCT01168388
39 MDs on Botox Utility (MOBILITY) Completed NCT00535938
40 Botulinum Toxin in the Treatment of Raynaud's Completed NCT01233999 Not Applicable botulinum toxin A
41 Cognitive Function and Emotional Possessing in Bilateral Facial Palsy Completed NCT02179450
42 Post Marketing Surveillance Study of Dysport Completed NCT00210431
43 Neurophysiological Markers in Patients With Craniofacial Dystonia and Their Relatives Completed NCT00082615
44 Blepharospasm Tools Recruiting NCT02780336
45 Photic Blink Reflex in People With Blepharospasm and Increased Blinking Recruiting NCT03263000
46 Effect of Lipid Based Eye Drops on Tear Film Lipid Layer Thickness Recruiting NCT03399292 Cationorm MD sine eye drops
47 The Dystonia Coalition Natural History and Biospecimen Repository for Isolated Dystonias Recruiting NCT01373424
48 Botulinum Toxin A Versus Steroids for the Treatment of Chronic Plantar Fasciitis Recruiting NCT02196155 Not Applicable Botulinum toxin A;cortisone;Saline
49 An RCT of a Patient-initiated Treatment Service for BEB and HFS Active, not recruiting NCT02577224 Not Applicable
50 HLA Screening in Reducing the Risk of Antiepileptic Drug-induced Cutaneous Adverse Reactions Not yet recruiting NCT03184597 Not Applicable

Search NIH Clinical Center for Blepharospasm

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: blepharospasm

Genetic Tests for Blepharospasm

Genetic tests related to Blepharospasm:

# Genetic test Affiliating Genes
1 Blepharospasm 29 DRD5

Anatomical Context for Blepharospasm

MalaCards organs/tissues related to Blepharospasm:

41
Eye, Brain, Testes, Spinal Cord, Bone, Bone Marrow, Thalamus

Publications for Blepharospasm

Articles related to Blepharospasm:

(show top 50) (show all 611)
# Title Authors Year
1
Blepharospasm and Hemifacial Spasm. ( 29239872 )
2018
2
Surgical Myectomy for Essential Blepharospasm and Hemifacial Spasm. ( 29239878 )
2018
3
Long-term Efficacy of Botulinum Neurotoxin-A Treatment for Essential Blepharospasm. ( 29376224 )
2018
4
Combined effects of rTMS and botulinum toxin therapy in benign essential blepharospasm. ( 29530449 )
2018
5
Effect of Botulinum Toxin A Treatment on Eyelid Pressure in Eyes with Blepharospasm. ( 29641935 )
2018
6
Benign Essential Blepharospasm: What We Know and What We Don't. ( 29239874 )
2018
7
The Facial Nerve and Selective Neurectomy for Treatment of Benign Essential Blepharospasm. ( 29239881 )
2018
8
Spinocerebellar Ataxia Type 31 with Blepharospasm. ( 29434122 )
2018
9
Altered functional connectivity in blepharospasm/orofacial dystonia. ( 29568690 )
2018
10
The Benign Essential Blepharospasm Research Foundation. ( 29239875 )
2018
11
Whole-exome sequencing for variant discovery in blepharospasm. ( 29770609 )
2018
12
Botulinum Toxins for Treating Essential Blepharospasm and Hemifacial Spasm. ( 29239877 )
2018
13
Secondary Blepharospasm Associated With Ocular Surface Disease. ( 29239879 )
2018
14
The History of Blepharospasm in Medicine. ( 29239873 )
2018
15
Oral Pharmacotherapy for Benign Essential Blepharospasm. ( 29239876 )
2018
16
Increase lipid tear thickness after botulinum neurotoxin A injection in patients with blepharospasm and hemifacial spasm. ( 29849166 )
2018
17
Developments in the treatment of benign essential blepharospasm. ( 29916840 )
2018
18
Treatment satisfaction with botulinum toxin: a comparison between blepharospasm and cervical dystonia. ( 29066869 )
2017
19
Nonmotor symptoms in primary adult-onset cervical dystonia and blepharospasm. ( 28239516 )
2017
20
An Aesthetic Orbicularis Oculi Myectomy Technique for Blepharospasm: Use of Topical 5-Fluorouracil and Fibrin Sealant. ( 28863116 )
2017
21
A comparative crossover study on the treatment of hemifacial spasm and blepharospasm: preseptal and pretarsal botulinum toxin injection techniques. ( 28884242 )
2017
22
Unilateral pallidotomy for blepharospasm refractory to botulinum toxin injections. ( 28643956 )
2017
23
Blepharospasm 40 years later. ( 28186662 )
2017
24
Treatment of blepharospasm with apraclonidine. ( 28017248 )
2017
25
(123)I-FP-CIT SPECT imaging in blepharospasm. ( 28629634 )
2017
26
Intractable Blepharospasm Treated with Bilateral Pallidal Deep Brain Stimulation. ( 28975046 )
2017
27
Management of Essential Blepharospasm. ( 28680527 )
2017
28
Treatment of Blepharospasm/Hemifacial Spasm. ( 28965229 )
2017
29
Depression in blepharospasm: a question of facial feedback? ( 28761348 )
2017
30
Sensory tricks in primary blepharospasm and idiopathic cervical dystonia. ( 28488615 )
2017
31
Surgical approach to limiting skin contracture following protractor myectomy for essential blepharospasm. ( 29403334 )
2017
32
Medical Cannabis, a Beneficial High in Treatment of Blepharospasm? An Early Observation. ( 29339959 )
2017
33
Correction: Grey Matter Microstructural Integrity Alterations in Blepharospasm Are Partially Reversed by Botulinum Neurotoxin Therapy. ( 28192485 )
2017
34
INCREASED BLINKING MAY BE A PRECURSOR OF BLEPHAROSPASM: A LONGITUDINAL STUDY. ( 29082270 )
2017
35
Resting state fMRI observations of baseline brain functional activities and connectivities in primary blepharospasm. ( 28893588 )
2017
36
Clinical heterogeneity in patients with idiopathic blepharospasm: A cluster analysis. ( 28476326 )
2017
37
A Dynamic Circuit Hypothesis for the Pathogenesis of Blepharospasm. ( 28326032 )
2017
38
Cluster Headache Associated with Secondary Unilateral Blepharospasm: A Case Report and Review of the Literature. ( 28540017 )
2017
39
Multiple Neural Networks Malfunction in Primary Blepharospasm: An Independent Components Analysis. ( 28539879 )
2017
40
Comparison of Safety and Efficacy of Botox and Neuronox in the Management of Benign Essential Blepharospasm: A Split-face Study. ( 29022290 )
2017
41
Blepharospasm as a masquerade of glaucomatous visual field defects. ( 28576231 )
2017
42
Sensitivity of Diagnostic Tests for Dry Eye in Patients with Blepharospasm. ( 29479902 )
2017
43
Edrophonium Challenge Test for Blepharospasm. ( 27375406 )
2016
44
Changes in ocular higher-order aberrations following botulinum toxin treatment in patients with blepharospasm : BTX improves dry eye in patients with BEB. ( 27503401 )
2016
45
Comparison of Two Botulinum Neurotoxin A Injection Patterns with or without the Medial Lower Eyelid in the Treatment of Blepharospasm. ( 26885381 )
2016
46
Cost-Effectiveness of Incobotulinumtoxin-A with Flexible Treatment Intervals Compared to Onabotulinumtoxin-A in the Management of Blepharospasm and Cervical Dystonia. ( 27021747 )
2016
47
Grey Matter Microstructural Integrity Alterations in Blepharospasm Are Partially Reversed by Botulinum Neurotoxin Therapy. ( 27992533 )
2016
48
Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache: Payment policy perspectives. ( 29443136 )
2016
49
A novel ANO3 variant identified in a 53-year-old woman presenting with hyperkinetic dysarthria, blepharospasm, hyperkinesias, and complex motorA tics. ( 27919237 )
2016
50
Blepharospasm in a multiplex African-American pedigree. ( 26944167 )
2016

Variations for Blepharospasm

ClinVar genetic disease variations for Blepharospasm:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 DRD5 DRD5, (CT/GT/GA)n undetermined variant risk factor

Expression for Blepharospasm

Search GEO for disease gene expression data for Blepharospasm.

Pathways for Blepharospasm

GO Terms for Blepharospasm

Biological processes related to Blepharospasm according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 adenylate cyclase-activating G-protein coupled receptor signaling pathway GO:0007189 9.32 DRD5 GNAL
2 activation of adenylate cyclase activity GO:0007190 9.26 DRD5 GNAL
3 negative regulation of blood pressure GO:0045776 9.16 DRD5 GCH1
4 adenylate cyclase-activating dopamine receptor signaling pathway GO:0007191 8.96 DRD5 GNAL
5 chaperone-mediated protein transport GO:0072321 8.62 TIMM8A TOR1A

Sources for Blepharospasm

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....